The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I dose-escalation study of talimogene laherparepvec (T-VEC) for advanced pancreatic cancer (ca).
Kenneth J. Chang
No relevant relationships to disclose
Neil N. Senzer
No relevant relationships to disclose
Kenneth Binmoeller
No relevant relationships to disclose
Howard Goldsweig
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Robert Coffin
Consultant or Advisory Role - Amgen
Stock Ownership - Amgen